Territory: IL, DC, VA, WV, OH, MIServing as a field-based extension of Medical Affairs, the Medical Science Liaison (MSL) will represent the Company, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies that target p53 mutations. The MSL will initially support Company’s lead product candidate, an orally available small molecule for the treatment of patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutatio